23/07/2018 Mayne Pharma Acquires Generic Efudex®, Complementing US Dermatology Portfolio
(WorldNews Health)

MAYNE PHARMA ACQUIRES GENERIC EFUDEX®, COMPLEMENTING US DERMATOLOGY PORTFOLIO Jul. 23 2018, Adelaide, South Australia o Mayne Pharma Group Limited ("Mayne Pharma") (ASX: MYX) has acquired generic Efudex® (fluorouracil cream 5%) from Spear Pharmaceuticals, Inc. ("Spear") for up to US$30.0 million o Product is immediately EPS accretive with an implied acquisition EBITDA multiple in the low single digits o Mayne Pharma will fund the acquisition from cash and undrawn debt Mayne Pharma is pleased to announce it has completed the acquisition of generic Efudex (fluorouracil cream 5%) from Spear Pharmaceuticals, Inc. for US$20.0 million (comprising US$16.0 million in cash and...